GLB1L2

Across TCGA pan-cancer cohorts, GLB1L2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated GLB1L2 data layer compared with 26 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher GLB1L2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated GLB1L2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where GLB1L2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.930	0.580	<.001	30	view →
LUAD	OS	Quartile	II,III,IV	0.902	0.282	.001	23	view →
PDAC	DFS	Median	III,IV	0.946	0.419	.017	8	view →
LSCC	DFS	Tertile	All	0.807	0.342	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

GLB1L2–CCRCC (DFS)

Open the CCRCC breakdown →